Opposite functions of HIF-α isoforms in VEGF induction by TGF-Β1 under non-hypoxic conditions

Oncogene

Volumn 30, Issue 10, 2011, Pages 1213-1228

  Chae, K S ^a,b   Kang, M J ^a   Lee, J H ^a   Ryu, B K ^a   Lee, M G ^a   Her, N G ^a   Ha, T K ^a   Han, J ^a   Kim, Y K ^a   Chi, S G ^a  

^a Korea University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

HIF 2 ; HuR; prostate cancer; Smad3; TGF 1; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOPROTEIN; MESSENGER RNA; SMAD BINDING ELEMENT 2; SMAD PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, SURFACE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952534509     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.498     Document Type: Article

References (55)

1. Benjamin D, Moroni C. (2007). mRNA stability and cancer: an emerging link? Expert Opin Biol Ther 7: 1515-1529. (Pubitemid 47597140)
2. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, Peters M et al. (2003). Transforming growth factor b1 stimulates vascular endothelial growth factor gene transcription in human cholangio-cellular carcinoma cells. Cancer Res 63: 1083-1092. (Pubitemid 36278442)
3. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. (2000). Relationship of hypoxia-inducible factor (HIF)-1a and HIF-2a expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60: 7106-7113. (Pubitemid 32059191)
4. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S et al. (2005). The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11: 7658-7663. (Pubitemid 41611607)
5. Brown JM, Wilson WR. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447. (Pubitemid 38745529)
6. Derynck R, Zhang YE. (2003). Smad-dependent and Smad-indepen-dent pathways in TGF-b family signaling. Nature 425: 577-584. (Pubitemid 37280136)
7. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA et al. (2001). Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 108: 1657-1665. (Pubitemid 33144876)
8. Fan XC, Steitz JA. (1998). HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci USA 95: 15293-15298. (Pubitemid 29018692)
9. Ferrara N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611. (Pubitemid 39099316)
10. Fukuda R, Kelly B, Semenza GL. (2003). Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglan-din E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63: 2330-2334. (Pubitemid 36538645)
11. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C et al. (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62: 854-859. (Pubitemid 34126964)
12. Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT et al. (2007). Mechanisms underlying TGF-b1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 81: 557-566.
13. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S et al. (2008). Hypoxia-inducible factor-2a correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68: 9212-9220.
14. Heldin CH, Miyazono K, ten Dijke P. (1997). TGF-b signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471. (Pubitemid 28013118)
15. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H et al. (2006). Recruitment of HIF-1a and HIF-2a to common target genes is differentially regulated in neuroblastoma: HIF-2a promotes an aggressive phenotype. Cancer Cell 10: 413-423. (Pubitemid 44693470)
16. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. (2003). Hypoxia-inducible factors 1a and 2a are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13: 493-501. (Pubitemid 37266952)
17. Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME. (2009). Role of the VEGFR3/VEGFD receptor axis in TGFb1 activation of primary prostate cell lines. Prostate 69: 982-990.
18. Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK et al. (2008). NF-kB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastro-enterology 135: 2030-2042.
19. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M et al. (1996). Loss of expression of transforming growth factor b type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2: 1255-1261. (Pubitemid 26299422)
20. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246. (Pubitemid 41039148)
21. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004. (Pubitemid 32476461)
22. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L et al. (2007). Hypoxia inducible factor-2a in cancer. Cell Cycle 6: 919-926.
23. Loureiro RM, D'Amore PA. (2005). Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 16: 77-89. (Pubitemid 40279118)
24. Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. (2007). Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 13: 5692-5702. (Pubitemid 47583893)
25. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. (2002). The contribution of VHL substrate binding and HIF1-a to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255. (Pubitemid 41039149)
26. Massague J. (1990). The transforming growth factor-b family. Ann Rev Cell Biol 6: 597-641.
27. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. (2006). Transforming growth factor b1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 281: 24171-24181. (Pubitemid 44274191)
28. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375: 577-581.
29. 0 untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 61: 2154-2161. (Pubitemid 32692041)
30. Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S et al. (2009). HIF-1a and HIF-2a are differentially regulated in vivo in neuroblastoma: high HIF-1a correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res 15: 7130-7136.
31. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I. (2006). Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 21: 857-865. (Pubitemid 44082728)
32. Park BJ, Park JI, Byun DS, Park JH, Chi SG. (2000). Mitogenic conversion of transforming growth factor-b1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res 60: 3031-3038.
33. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS et al. (2003). Transforming growth factor-b1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kB, JNK, and Ras signaling pathways. Oncogene 22: 4314-4332. (Pubitemid 36897963)
34. Pietras A, Gisselsson D, Ora I, Noguera R, Beckman S, Navarro S et al. (2008). High levels of HIF-2a highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol 214: 482-488. (Pubitemid 351340568)
35. Pu H, Collazo J, Jones E, Gayheart D, Sakamoto S, Vogt A et al. (2009). Dysfunctional transforming growth factor-b receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res 69: 7366-7374.
36. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686. (Pubitemid 40853601)
37. Ryan HE, Lo J, Johnson RS. (1998). HIF-1a is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015. (Pubitemid 28254373)
38. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C. (2001). Synergistic cooperation between hypoxia and transforming growth factor-b pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535.
39. 2 homeostasis. Curr Opin Genet Dev 8: 588-594. (Pubitemid 28477364)
40. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. (Pubitemid 37328811)
41. Shi Y, Massague J. (2003). Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113: 685-700. (Pubitemid 36724933)
42. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. (1999). Role of interleukin 10 and transforming growth factor b1 in the angiogen-esis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5: 711-720. (Pubitemid 29131984)
43. Sugano Y, Matsuzaki K, Tahashi Y, Furukawa F, Mori S, Yamagata H et al. (2003). Distortion of autocrine transforming growth factor b signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene 22: 2309-2321. (Pubitemid 36566786)
44. Tran H, Maurer F, Nagamine Y. (2003). Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 23: 7177-7188. (Pubitemid 37211000)
45. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. (1993). Association of transforming growth factor-b1 with prostate cancer: an immunohistochemical study. Human Pathology 24: 4-9. (Pubitemid 23046665)
46. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E et al. (2004). Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1a and HIF-2a expression in lung epithelial cells: implication of natural antisense HIF-1a. J Biol Chem 279: 14871-14878.
47. 2 tension. Proc Natl Acad Sci USA 92: 5510-5551.
48. Wang L, Kwak JH, Kim SI, He Y, Choi ME. (2004). Transforming growth factor-b1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase 3-p38a and p38d mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem. 279: 33213-33219. (Pubitemid 39062967)
49. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M. (2000). HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 19: 2340-2350. (Pubitemid 30259015)
50. Wang W, Yang X, Cristofalo VJ, Holbrook NJ, Gorospe M. (2001). Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence. Mol Cell Biol 21: 5889-5898. (Pubitemid 32737806)
51. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL et al. (1996). Reduced levels of transforming growth factor b receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 2: 635-640. (Pubitemid 26135335)
52. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S et al. (2004). Prognostic impact of hypoxia-inducible factors 1a and 2a in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10: 8554-8560. (Pubitemid 40053424)
53. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545. (Pubitemid 30183422)
54. Zhong H, Semenza GL, Simons JW, De Marzo AM. (2004). Up-regulation of hypoxia-inducible factor 1a is an early event in prostate carcinogenesis. Cancer Detect Prev 28: 88-93. (Pubitemid 38448745)
55. Zhu B, Kyprianou N. (2005). Transforming growth factor b and prostate cancer. Cancer Treat Res 126: 157-173.